Prostate Cancer Program
The overarching mission of the Prostate Cancer Program (PC) is to reduce prostate cancer incidence and mortality in the SKCC catchment area and beyond. PC investigators are focused on understanding the basis of prostate cancer development and progression, developing new clinical interventions to reduce prostate cancer incidence and mortality, and designing/testing interventions in populations.
The Prostate Cancer Program (PC) is led by Wm. Kevin Kelly DO and legacy Co-Leaders Leonard Gomella MD and Alessandro Fatatis MD PhD (DU consortium member). The Program is comprised of 28 basic, population, and clinical researchers who developed robust mechanisms for conducting interdisciplinary and transdisciplinary research. PC members have expertise in all aspects of prostate cancer research, resulting in multiple collaborative grants and high impact publications. The overarching PC mission is to reduce prostate cancer incidence and mortality in our catchment area and beyond, with an emphasis on vulnerable populations (including African-Americans and geriatric patients). PC members are focused on understanding the basis of prostate cancer development and progression, developing new clinical interventions to reduce prostate cancer incidence and mortality, and designing and testing interventions in populations. They continuously look to generate a paradigm-shifting and practice-changing discoveries.
Program Leader- Wm Kevin Kelly DO has served as PC Leader since 2015, succeeding its founding leader, Dr. Knudsen. Dr. Kelly is an internationally respected clinical researcher and leader in the genitourinary (GU) oncology field. He has held multiple leadership positions in the Cancer and Leukemia Group B, including serving as the PI for multiple Phase II/III studies, and is an active member of ECOG/ACRIN and NRG. Dr. Kelly has expertise in drug and biomarker development in prostate and bladder cancer, and has been instrumental in defining the use of many novel therapies and biomarkers in patients for all stages of prostate cancer. Reflecting his national reputation, he was a member of the Oncologic Drugs Advisory Committee for the FDA and currently serves on the NCI Prostate Cancer Task Force. Dr. Kelly is PI of several key IITs based on discoveries emanating from the PC Program. Prior to joining SKCC, he co-led the Genitourinary Oncology Program at Yale Cancer Center and was Medical Director of the Yale Clinical Management Research Office. He is Director of the Solid Tumor Division in the Department of Medical Oncology and Associate Director (AD) of Clinical Research at SKCC.
Co-Leader Alessandro Fatatis MD PhD (Co-Leader since 2012) is a Professor of Pharmacology and Pathology and the Director of the MD/PhD Program at Drexel University College of Medicine (DU). He is a highly productive scientist with expertise in the bone tropism of hormone dependent cancers, who developed novel preclinical animal models for identification and validation of therapeutic strategies to counteract metastases. His findings supported development of the human antibody IMC-3G3 for targeting Platelet-Derived Growth Factor Receptor Alpha (PDGFRα) in metastatic prostate cancer and led to a patent (US 8,425,91). Now renamed Olaratumab, this agent is being investigated by Lilly Oncology in clinical trials for a variety of solid tumors. Dr. Fatatis also identified CX3CR1 as a crucial player in the seeding and progression of prostate and breast skeletal metastases. In collaboration with Drs. Salvino and Meucci from Drexel University he has synthesized and is testing novel small-molecule antagonists against CX3CR1. This drug discovery and development program generated two published patents (US 8,435,993 and US 9,375,474), was approved for support by the NCI Experimental Therapeutics (NExT) Program, led to the formation of a new start-up company, Kerberos Biopharmaceuticals Inc., and has attracted funding from NIH (R01, R21, SBIR), US Department of Defense (Breakthrough Award II), and the Coulter Foundation. Dr. Fatatis’ leadership galvanized new collaborations across SKCC resulted impactful discoveries, facilitated by his expertise in the metastatic processes.
Co-Leader Leonard Gomella MD has served in this role since 2013. Dr. Gomella is the Bernard W. Godwin, Jr. Professor and Chair of Urology at TJU and SKCC. Dr. Gomella also serves as the Urology Chair for NRG Oncology (formerly RTOG). Dr. Gomella is involved in both translational science and clinical research in the development of new diagnostic techniques and treatments for prostate, bladder and kidney cancer. In addition to serving on numerous editorial boards, he is Editor-in-Chief of the Canadian Journal of Urology. Dr. Gomella is well known for the Clinician's Pocket Reference, now in its 11th edition, and the annual Clinician's Pocket Drug Reference, both widely used general medical references. He served as President of the Mid-Atlantic Section of the American Urological Association (AUA) and has been elected to the American Association of Genitourinary Surgeons and the prestigious Clinical Society of Genitourinary Surgeons. In 2015, he became President of the Society of Urologic Oncology, and recipient of the Distinguished Contribution Award from the AUA.
DEN, ROBERT B
DICKER, ADAM P.
GOMELLA, LEONARD G.
HALPERN, ETHAN J.
KELLY, WILLAM KEVIN
KNUDSEN, KAREN E
THAKUR, MADHUKAR L (MATHEW)